On October 28th, Haoyuan Pharmaceutical (688131.SH) announced that, due to the shareholder's own financial needs, Suxin Fund plans to reduce its shareholding by no more than 4,513,877 shares of the company through centralized bidding or block trading, with a reduction ratio not exceeding 2.14% of the company's current total share capital. Among them, it plans to reduce the number of shares held through centralized bidding by no more than 2,109,288 shares, accounting for no more than 1% of the total share capital, and the total number of shares to be reduced within any consecutive 90 natural days shall not exceed 1% of the total shares of the company; it plans to reduce the number of shares held through block trading by no more than 2,404,589 shares, accounting for no more than 1.14% of the total share capital, and the total number of shares to be reduced within any consecutive 90 natural days shall not exceed 2% of the total shares of the company. During this shareholding reduction period, the reduction through centralized bidding or block trading shall be completed within 3 months after the announcement of the reduction plan, starting from 15 trading days after the disclosure date.

Due to fund maturity, shareholder's own financial needs and arrangements, Zhenjin Investment plans to reduce its shareholding by no more than 2,531,145 shares of the company through centralized bidding or block trading, with a reduction ratio not exceeding 1.20% of the company's current total share capital. Among them, it plans to reduce the number of shares held through centralized bidding by no more than 2,109,288 shares, accounting for no more than 1% of the total share capital; it plans to reduce the number of shares held through block trading by no more than 421,857 shares, accounting for no more than 0.2% of the total share capital. The reduction through centralized bidding or block trading shall be completed within 3 months after the announcement of the reduction plan, starting from 3 trading days after the disclosure date.